For citation purposes: Hagiwara N. Muscle fibre types: their role in health, disease and as therapeutic targets. OA Biology 2013 Nov 01;1(1):2.

Review

 
Development

Muscle fibre types: their role in health, disease and as therapeutic targets

N Hagiwara*
 

Authors affiliations

Department of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, California, USA

* Corresponding author Email: nhagiwara@ucdavis.edu

Abstract

Introduction

Accounting for approximately half of the body weight, the skeletal muscle is the largest organ in the human body. The functional significance of the muscle is seen in the two-fold purpose it serves–as a source of force production for locomotion and as a major regulatory organ for glucose and fatty acid metabolism. This short review will focus on muscle fibre types, starting with a brief historical overview of fibre types, their physiological and metabolic significance, how fibre type plasticity affects both contractile and metabolic properties of muscle and how these properties relate to human diseases known to exhibit muscle fibre type (slow-twitch vs. fast-twitch) disproportion. Also, based on recent animal model experiments, this paper discusses the efficacy of using fibre type manipulation for therapeutic purposes.

Conclusion

Because of its adaptability to external stimuli and easy accessibility, skeletal muscle remodeling could be a viable therapeutic approach for various diseases manifesting fibre type shifts. Reduced ratios of slow-oxidative muscle are significantly associated with obesity and type 2 diabetes. Recent information obtained from animal model studies for metabolic syndrome and muscle atrophy present multiple candidate genes and signaling pathways for use as therapeutic targets. As more detailed molecular mechanisms of fibre type specification and plasticity are revealed, manipulating physiological properties of skeletal muscle holds a promise for treatment of obesity-induced clinical conditions as well as muscle atrophy.

Introduction

Heterogeneity is the foundation for the functional plasticity of the skeletal muscle. Muscle fibres contain a bundle of myofibrils, which consist of tandem repeats of sarcomeres, the contractile unit of skeletal muscle (Figure 1). The defining physiological properties of each muscle fibre–its contraction speed (slow/fast) and metabolic capacity (oxidative/glycolytic)–are a functional culmination of the coordinated expression of numerous sarcomeric contractile protein isoforms and metabolic enzymes. Therefore, the functionality of each muscle fibre is a summation of these properties and the resultant combination is termed ‘fibre type’. Visual recognition of muscle fibre type–red versus white–has been reported for centuries[1]; however, only in the past 50 years has the extent of heterogeneity of muscle been fully appreciated. As an organ, human muscle is a checker board of these heterogeneous fibre types, allowing remarkable adaptation to various tasks requiring different degrees of intensity and duration.

Skeletal muscle fibre.

Although muscle fibre type specification occurs during development[2], fibre type is not static in adult life. In addition to the activity-induced functional plasticity seen in normal adult muscle, disuse of muscle and disease-induced pathologies can selectively influence muscle fibre types, inducing different responses between fibre types. One common response associated with pathologic conditions is the predominance of one fibre type over the others. This phenomenon has been recognized as a significant clinical feature for human neuromuscular diseases over 40 years[3]. In spite of this decades old observation, three major unknowns still remain for any given disease: (1) what determines the differential responses between muscle fibre types, (2) whether predominance of one fibre type is causal or secondary to the pathological condition and (3) whether manipulating muscle fibre type can improve pathological conditions associated with fibre type predominance. Answers to the first two questions remain elusive; however, promising data have been obtained in recent years through the use of genetically engineered animal models to address the third issue, which in turn gives clues to answer the first two questions. The aim of this review is to discuss muscle fibre types and their role in health, disease and as therapeutic targets.

Discussion

The author has referenced some of his own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies. Animal care was also in accordance with the institution guidelines.

Fibre type classification

Historically muscle fibre classification was performed visually, resulting in the classic ‘red’ and ‘white’ muscle terminology[1]. In the 1970s, histochemical analysis of myosin ATPase activity (still in use today) expanded the red/white distinction into three distinct fibre types, type 1, 2A and 2B (slow to fast respectively)[4]. It was not until the late 1980s that the development of isoform-specific myosin heavy chain (MyHC) monoclonal antibodies and single fibre analysis revealed that there are actually more than three fibre types in mammalian skeletal muscle[5,6]. While interpreting cross-species data, it is important to bear in mind species differences in histochemical ATPase classification to avoid confusion. It is now known that there are major species differences in the nature of classically defined type 2B fibres–particularly between small mammals such as rodents and large mammals such as humans[7,8] (Figure 2). Good historical overviews covering the evolution of fibre types[7,8] and the importance of hybrid fibres (expressing more than one MyHC isoform)[9,10] can be found in the literature.

Contractions speeds of the MyHC isoforms (ATPase activity: lower to higher).

Another important fibre type trait is metabolic capacity (i.e. oxidative and glycolytic metabolism). In adult skeletal muscle, contractile speed dictated by the MyHC ATPase activity is correlated with the spectrum of metabolic capacity; simply put, slow type I is high in mitochondrial content thus in oxidative enzymes (slow-oxidative), type2A–oxidative and glycolytic (fast oxidative-glycolytic), and type 2B–high in glycolytic enzymes and lowest in mitochondrial content (fast-glycolytic). Recently, functional specialization in mitochondria between oxidative and glycolytic fibres has been reported[11], adding yet more differential parameters for fibre type diversity.

Muscle fibre type in healthy and disease conditions

Muscle fibre type properties are modulated and maintained by electronic stimulations from motoneurons. Like skeletal muscle fibres, motoneurons are not made equal; different subsets of motoneurons stimulate muscle with distinctive frequencies[12,13], maintaining muscle fibre types in accordance with firing frequencies–higher frequencies of stimulation induce and maintain faster contracting and lower frequencies, slower contracting fibre type[14,15,16]. Therefore, specialized exercise regimens (aerobic or anaerobic) can induce a significant change towards slow oxidative or fast glycolytic transition[17,18,19]. Disuse of muscle also induces fibre type shift, in this case, from slow towards fast. In a microgravity environment (space flight) or bed rest, both of which largely release muscle from its weight bearing function, a measurable shift occurs from slow-oxidative towards fast-glycolytic[20,21,22]. In the muscle-disuse conditions, atrophy was also prominent in the muscle rich in slow-oxidative fibres[20,23].

In daily life, though our living situation is not as extreme as microgravity, a sedentary life style resulting in decreased muscle activity is becoming more common. A recent report portends worsening health conditions in the Unites States by revealing significant increases in obesity, hypertension, hypercholesterolemia and diabetes in baby boomers, attributable to declining physical activity in American adults[24]. One might predict that in lifestyle-induced pathological conditions, skeletal muscle properties would exhibit similar changes to those seen in un-weighted muscle. Indeed, it has been reported that high-BMI (body mass index) individuals with insulin resistance and patients of type 2 diabetes exhibit decreased slow-oxidative fibres concurrent with increased fast-glycolytic fibres[25,26,27].

Gene expression profiling supports these observations at the molecular level; expression of the genes involved in oxidative metabolism is significantly decreased in pre-diabetic and type 2 diabetic individuals[28,29,30]. These reports collectively establish that insulin resistance and type 2 diabetes are strongly linked with reduced slow-oxidative fibre content and oxidative metabolic capacity.

Oxygen accessibility is also a significant factor affecting muscle fibre type proportion. Because of their heavy reliance on oxygen for ATP synthesis, hypoxic conditions are inhospitable for slow-oxidative fibres. Fibre type proportion in the limb muscle of chronic obstructive pulmonary disease (COPD)[31,32,33,34] and chronic heart failure (CHF)[35,36,37,38] patients show significant shifts from slow-oxidative towards fast-glycolytic. Together, the significant decrease in slow-oxidative fibres and reduction in oxidative metabolic capacity leads to exercise intolerance in COPD and CHF patients, substantially affecting their quality of life[39].

To begin addressing the topic of fibre types and congenital muscle disease, I would like to quote the opening sentence from Engle’s prescient review written in 1970[3]: ‘During the past few years, our studies of the histochemical changes of skeletal muscle in human neuromuscular diseases and experimental animal models have gradually led to the development of an analytical approach which places major emphasis upon determining whether there is selective or non-selective involvement of muscle fibre types in each human and animal condition studied’. Historically, at this point, only two types of fibres (I and II) were identified; however, even with this limitation it was clear that in many muscle diseases, there was a shift in the normally observed fibre type ratios or morphologies. With the advent of increased molecular diagnostics, many of the underlying mutations are coming to light, thinning out what has historically been a nosological minefield[40]. For example, a group of congenital myopathies with heterogeneous aetiologies known as congenital fibre type disproportion show morphological variance; type I fibres are consistently smaller than type II. According to this, mutations in at least four genes are known to lead to this disease[40,41]. Another common observation is variation of fibre type ratios, as seen in the monogenic disease Duchenne muscular dystrophy (DMD) which is caused by the loss of a functional dystrophin gene[42]. Dystrophin is expressed in all fibre types, and as the disease progresses, all muscle fibres in the proximal muscle of DMD patients succumb to degeneration; however, in the progression of the disease, it is the fast-glycolytic fibres that are the first to degenerate[43,44]. In the limb muscle of mdx mutant mice, a mouse model for DMD, fast fibres are more susceptible to degeneration–regeneration cycles, though the muscle pathology is far less severe than DMD[45]. The biological basis for this preferential degeneration of fast fibres in DMD muscle is not known. One hypothesis is that type 2B fibres are more susceptible to damage because of the mechanical stress caused by the rapid and forceful contraction of fast muscle[43,44]. This proposal was corroborated by the observation that in the mdx mice limb, fast muscles are more susceptible to contraction-induced injuries than the slow fibre-rich muscle[46].

Regulatory factors for fibre type specification

Mouse models have been instrumental in identifying genes involved in fibre type specification of mammalian skeletal muscle. I will discuss three categories of regulatory molecules reported to direct coordinate expression of fibre type specific genes. The goal here is not to present a complete list, but rather to present ideas of the nature of regulatory pathways involved in muscle fibre type specification.

Transcription factors regulating development

In recent years, transcription factors orchestrating expression of muscle fibre type-specific genes have been identified. Initially, the main focus was how fast and slow motoneuron-specific stimulation is converted into intracellular signals to initiate necessary transcriptional events for fibre type specification. When the skeletal muscle is electrically stimulated, Ca[2+] is released from sarcoplasmic reticulum to initiate contraction. In slow fibre specification, this Ca[2+] burst leads to activation of the NFAT[47,48,49] and Mef2 transcription factor families[50,51]. Together, these transcription factors play significant roles in slow fibre-specific gene transcription in response to motoneuron stimulation.

More recently, the transcription factors regulating muscle fibre type differentiation during development have started to be identified. Our laboratory showed that inactivation of the Sox6 transcription factor in muscle leads to a major shift in fibre type from fast to slow[52,53,54]. Using ChIP-seq, we have shown that Sox6 suppresses transcription of slow fibre-specific genes by directly binding to their regulatory sequences in vivo[52]. Sox6-null skeletal muscle also shows increased tolerance against fatigue[55], an oxidative fibre characteristic, indicating that Sox6 may be involved in the regulation of metabolic adaptation in the skeletal muscle. In line with these observations, the human SOX6 gene has been shown to be associated with obesity risk[56,57], suggesting the likelihood that Sox6 is involved in orchestrating the overall fibre type properties by repressing genes involved in the slow fibre phenotype.

In addition to transcriptional suppressors, activators of fibre type-specific genes have also been identified. For example, Tead1 and Six1/Six4 transcription factors have been shown to be necessary for activation of slow and fast fibre-specific genes, respectively[58,59]. It has been shown that muscle-specific Tead1 transgenic mice exhibit an increase of slow-oxidative fibres at the expense of fast-glycolytic fibres[60] and Six1/Six4 knockout mice show decrease in fast fibre differentiation in embryonic muscle[61].

Nuclear receptors and cofactor for energy metabolism

As the largest metabolic organ in the body, skeletal muscle is heavily influenced by, and in turn, highly influential on the metabolic state of the body. The dynamic status of glucose and fatty acids in the body has a significant influence on muscle fibre type regulation by altering the balance of oxidative (slow) and glycolytic (fast) fibres. One of the conduits for this influence is through ligands (fatty acids and their derivatives) interacting with nuclear receptors.

The peroxisome proliferator-activated receptors (PPARs) (α, β/δ, γ) are ligand-activated nuclear receptors[62]. Among them, PPARs α and β/δ have been shown to stimulate expression of genes for fatty acid oxidation in muscle[63,64]. Indeed, muscle-specific PPAR δ transgenic mice displayed a significant increase in both oxidative metabolic enzyme expression and type 1 fibres[65]. More recently, another family of nuclear receptors, the oestrogen receptor-related receptors (specifically, ERRγ), have been reported to stimulate the formation of not only slow-oxidative fibres but also vascularization[66,67], further expanding the involvement of nuclear receptors in metabolism-induced skeletal muscle remodelling.

Nuclear receptor functions are modulated by co-activators and/or co-repressors. PGC-1α, a co-activator of multiple lipid-activated nuclear receptors, plays a major role in mitochondrial biogenesis and regulation of oxidative phosphorylation[68]. Muscle-specific PGC-1α overexpression in mice leads to a significant increase in slow-oxidative fibres[69]. Conversely, nuclear receptor co-repressors suppress slow-oxidative fibre formation. Nuclear receptor corepressor 1 (NCoR1) antagonizes PGC-1a, thus suppressing oxidative metabolism in muscle[70,71].

MicroRNA

Muscle-specific microRNA plays a significant role in muscle fibre type regulation by addition of post-transcriptional regulation[72,73]. miR-499 has been shown to target Sox6[74,75]. Muscle-specific miR-499 overexpression in mice significantly increases expression of slow fibre-specific contractile protein genes, presumably by suppressing Sox6 activity[75]. In addition, microRNAs, whose expression is altered by physical activity have been reported[76,77], predicting the expanding role of miRNAs in skeletal muscle plasticity.

Therapeutic potential of muscle fibre remodelling for ameliorating muscle pathology

Recently researchers have shown that it is possible to manipulate muscle fibre type in vivo. Coordinated changes in muscle fibre type-specific genes shaping contractile and metabolic capacities observed in the genetically engineered mouse models discussed above have begun to reveal the therapeutic possibilities of muscle fibre type remodelling.

To date, multiple mouse models have been created that genetically increase type 1 fibres. These have been used to test the hypothesis that muscle enriched with slow-oxidative fibres can improve pathophysiology and force production in mdx mice (the mouse model for DMD). The results have shown promise. The higher content of type 1 fibres in mdx mice, induced by a PGC-1α transgene[78], transfection of the Wnt7a gene[79], or activation of calcineurin[80,81,82], all displayed decreased mechanical injury and improved force production. Of note, utrophin, a structurally and functionally similar protein to dystrophin, which is more abundantly expressed in type 1 slow fibres[83] is likely the basis for this improvement. Despite the physiological differences in human and mouse skeletal muscles, these emerging data point to the use of fibre type remodelling for amelioration of muscle degenerative pathology.

How can we take advantage of these discoveries? Pharmacological activation of some of the regulatory pathways discussed above has shown promise. For example, selective activation of PPARδ or AMP-activated protein kinase (a target of ERRγ[66]) had beneficial effects on mdx muscle pathology and significantly improved exercise capacity[84,85]. Therefore, with the ever increasing understanding of fibre type regulation, coupled with the growing ability to manipulate fibre type in vivo, the ability to remodel our skeletal muscle fibre types to alleviate muscle pathology or to expedite weight loss[86] to improve our overall health appears on the horizon.

Conclusion

Skeletal muscle is highly adaptive to external stimulations even in adult. Because of its easy accessibility, identifying targets for effective muscle remodeling could provide new approaches to treat various disease conditions manifesting fibre type shifts, such as type 2 diabetes and COPD. Animal model studies for metabolic syndrome and muscle atrophy have identified multiple genes whose expression can be manipulated to reduce weight gain and muscle wasting, providing new therapeutic target candidates. As more detailed molecular mechanisms of fibre type specification and plasticity are revealed, manipulating physiological properties of skeletal muscle holds a promise for treatment of obesity-induced clinical conditions as well as muscle atrophy.

Abbreviations list

BMI, body mass index; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; DMD, Duchenne muscular dystrophy; MyHC, myosin heavy chain; NCoR1, nuclear receptor corepressor 1; PPARs, peroxisome proliferator-activated receptors.

Authors contribution

All authors contributed to the conception, design, and preparation of the manuscript, as well as read and approved the final manuscript.

Competing interests

None declared.

Conflict of interests

None declared.

A.M.E

All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.

References

  • 1. Needham DM . Red and white muscle. Physiol Rev 1926 Jan;6(1):1-27.
  • 2. Biressi S, Molinaro M, Cossu G. Cellular heterogeneity during vertebrate skeletal muscle development. Dev Biol 2007 Aug;308(2):281-93.
  • 3. Engel WK . Selective and nonselective susceptibility of muscle fiber types. A new approach to human neuromuscular diseases. Arch Neurol 1970 Feb;22(2):97-117.
  • 4. Brooke MH, Kaiser KK. Muscle fiber types: how many and what kind?. Arch Neurol 1970 Oct;23(4):369-79.
  • 5. Schiaffino S, Gorza L, Sartore S, Saggin L, Ausoni S, Vianello M. Three myosin heavy chain isoforms in type 2 skeletal muscle fibres. J Muscle Res Cell Motil 1989 Jun;10(3):197-205.
  • 6. Termin A, Staron RS, Pette D. Myosin heavy chain isoforms in histochemically defined fiber types of rat muscle. Histochemistry 1989;92(6):453-7.
  • 7. Pette D, Peuker H, Staron RS. The impact of biochemical methods for single muscle fibre analysis. Acta Physiol Scand 1999 Aug;166(4):261-77.
  • 8. Schiaffino S . Fibre types in skeletal muscle: a personal account. Acta Physiol (Oxf) 2010 Aug;199(4):451-63.
  • 9. Stevens L, Bastide B, Bozzo C, Mounier Y. Hybrid fibres under slow-to-fast transformations: expression is of myosin heavy and light chains in rat soleus muscle. Pflugers Arch 2004 Aug;448(5):507-14.
  • 10. Pette D, Staron RS. Transitions of muscle fiber phenotypic profiles. Histochem Cell Biol 2001 May;115(5):359-72.
  • 11. Picard M, Hepple RT, Burelle Y. Mitochondrial functional specialization in glycolytic and oxidative muscle fibers: tailoring the organelle for optimal function. Am J Physiol Cell Physiol 2012 Feb;302(4):C629-41.
  • 12. Hennig R, Lømo T. Firing patterns of motor units in normal rats. Nature 1985 Mar;314(6007):164-6.
  • 13. Hughes SM, Salinas PC. Control of muscle fibre and motoneuron diversification. Curr Opin Neurobiol 1999 Feb;9(1):54-64.
  • 14. Buller AJ, Eccles JC, Eccles RM. Interactions between motoneurones and muscles in respect of the characteristic speeds of their responses. J Physiol 1960 Feb;150417-39.
  • 15. Gorza L, Gundersen K, Lømo T, Schiaffino S, Westgaard RH. Slow-to-fast transformation of denervated soleus muscles by chronic high-frequency stimulation in the rat. J Physiol 1988 Aug;402627-49.
  • 16. Ausoni S, Gorza L, Schiaffino S, Gundersen K, Lømo T. Expression of myosin heavy chain isoforms in stimulated fast and slow rat muscles. J Neurosci 1990 Jan;10(1):153-60.
  • 17. Green HJ, Klug GA, Reichmann H, Seedorf U, Wiehrer W, Pette D. Exercise-induced fibre type transitions with regard to myosin, parvalbumin, and sarcoplasmic reticulum in muscles of the rat. Pflugers Arch 1984 Apr;400(4):432-8.
  • 18. Green HJ, Reichmann H, Pette D. Fibre type specific transformations in the enzyme activity pattern of rat vastus lateralis muscle by prolonged endurance training. Pflugers Arch 1983 Nov;399(3):216-22.
  • 19. Baumann H, Jäggi M, Soland F, Howald H, Schaub MC. Exercise training induces transitions of myosin isoform subunits within histochemically typed human muscle fibres. Pflugers Arch 1987 Aug;409(4–5):349-60.
  • 20. Sandona D, Desaphy JF, Camerino GM, Bianchini E, Ciciliot S, Danieli-Betto D. Adaptation of mouse skeletal muscle to long-term microgravity in the MDS mission. PLoS One 2012;7(3):e33232.
  • 21. Harrison BC, Allen DL, Girten B, Stodieck LS, Kostenuik PJ, Bateman TA. Skeletal muscle adaptations to microgravity exposure in the mouse. J Appl Physiol 2003 Dec;95(6):2462-70.
  • 22. Trappe S, Trappe T, Gallagher P, Harber M, Alkner B, Tesch P. Human single muscle fibre function with 84 day bed-rest and resistance exercise. J Physiol 2004 Jun;557(Pt 2):501-13.
  • 23. Thomason DB, Booth FW. Atrophy of the soleus muscle by hindlimb unweighting. J Appl Physiol (1985) 1990 Jan;68(1):1-12.
  • 24. King DE, Matheson E, Chirina S, Shankar A, Broman-Fulks J. The status of baby boomers’ health in the United States: the healthiest generation?. JAMA Intern Med 2013 Mar;173(5):385-6.
  • 25. Mårin P, Andersson B, Krotkiewski M, Björntorp P. Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care 1994 May;17(5):382-6.
  • 26. Oberbach A, Bossenz Y, Lehmann S, Niebauer J, Adams V, Paschke R. Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care 2006 Apr;29(4):895-900.
  • 27. Stuart CA, McCurry MP, Marino A, South MA, Howell ME, Layne AS. Slow-twitch fiber proportion in skeletal muscle correlates with insulin responsiveness. J Clin Endocrinol Metab 2013 May;98(5):2027-36.
  • 28. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003 Jul 8;100(14):8466-71.
  • 29. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003 Jul;34(3):267-73.
  • 30. Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS. Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 2002 Jun;51(6):1913-20.
  • 31. Maltais F, Sullivan MJ, LeBlanc P, Duscha BD, Schachat FH, Simard C. Altered expression of myosin heavy chain in the vastus lateralis muscle in patients with COPD. Eur Respir J 1999 Apr;13(4):850-4.
  • 32. Satta A, Migliori GB, Spanevello A, Neri M, Bottinelli R, Canepari M. Fibre types in skeletal muscles of chronic obstructive pulmonary disease patients related to respiratory function and exercise tolerance. Eur Respir J 1997 Dec;10(12):2853-60.
  • 33. Gosker HR, van Mameren H, vanDijk PJ, Engelen MP, van der Vusse GJ, Wouters EF. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 2002 Apr;19(4):617-25.
  • 34. Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax 2007 Nov;62(11):944-9.
  • 35. Sullivan MJ, Duscha BD, Klitgaard H, Kraus WE, Cobb FR, Saltin B. Altered expression of myosin heavy chain in human skeletal muscle in chronic heart failure. Med Sci Sports Exerc 1997 Jul;29(7):860-6.
  • 36. Schaufelberger M, Eriksson BO, Grimby G, Held P, Swedberg K. Skeletal muscle fiber composition and capillarization in patients with chronic heart failure: relation to exercise capacity and central hemodynamics. J Cardiac Fail 1995 Sep;1(4):267-72.
  • 37. Szentesi P, Bekedam MA, van Beek-Harmsen BJ, van der Laarse WJ, Zaremba R, Boonstra A. Depression of force production and ATPase activity in different types of human skeletal muscle fibers from patients with chronic heart failure. J Appl Physiol 2005 Dec;99(6):2189-95.
  • 38. Godard MP, Whitman SA, Song YH, Delafontaine P. Skeletal muscle molecular alterations precede whole-muscle dysfunction in NYHA Class II heart failure patients. Clinic Interv Aging 2012;7489-97.
  • 39. Middlekauff HR . Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail 2010 Jul;3(4):537-46.
  • 40. Goebel HH . Congenital myopathies Introduction. Semin Pediatr Neurol 2011 Dec;18(4):213-5.
  • 41. Clarke NF . Congenital fiber-type disproportion. Semin Pediatr Neurol 2011 Dec;18(4):264-71.
  • 42. Hoffman EP, Knudson CM, Campbell KP, Kunkel LM. Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature 1987 Dec;330(6150):754-8.
  • 43. Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 1988 Feb;52(4):503-13.
  • 44. Pedemonte M, Sandri C, Schiaffino S, Minetti C. Early decrease of IIx myosin heavy chain transcripts in Duchenne muscular dystrophy. Biochem Biophys Res Commun 1999 Feb 16;255(2):466-9.
  • 45. Marshall PA, Williams PE, Goldspink G. Accumulation of collagen and altered fiber-type ratios as indicators of abnormal muscle gene expression in the mdx dystrophic mouse. Muscle Nerve 1989 Jul;12(7):528-37.
  • 46. Consolino CM, Brooks SV. Susceptibility to sarcomere injury induced by single stretches of maximally activated muscles of mdx mice. J Appl Physiol 2004 Feb;96(2):633-8.
  • 47. Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 1998 Aug;12(16):2499-509.
  • 48. McCullagh KJ, Calabria E, Pallafacchina G, Ciciliot S, Serrano AL, Argentini C. NFAT is a nerve activity sensor in skeletal muscle and controls activity-dependent myosin switching. Proc Natl Acad Sci U S A 2004 Jul;101(29):10590-5.
  • 49. Schiaffino S, Serrano A. Calcineurin signaling and neural control of skeletal muscle fiber type and size. Trends Pharmacol Sci 2002 Dec;23(12):569-75.
  • 50. Wu H, Naya FJ, McKinsey TA, Mercer B, Shelton JM, Chin ER. MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type. EMBO J 2000 May;19(9):1963-73.
  • 51. Wu H, Rothermel B, Kanatous S, Rosenberg P, Naya FJ, Shelton JM. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J 2001 Nov;20(22):6414-23.
  • 52. An CI, Dong Y, Hagiwara N. Genome-wide mapping of Sox6 binding sites in skeletal muscle reveals both direct and indirect regulation of muscle terminal differentiation by Sox6. BMC Dev Biol 2011 Oct;1159.
  • 53. Hagiwara N, Ma B, Ly A. Slow and fast fiber isoform gene expression is systematically altered in skeletal muscle of the Sox6 mutant, p100H. Dev Dyn 2005 Oct;234(2):301-11.
  • 54. Hagiwara N, Yeh M, Liu A. Sox6 is required for normal fiber type differentiation of fetal skeletal muscle in mice. Dev Dyn 2007 Aug;236(8):2062-76.
  • 55. Quiat D, Voelker KA, Pei J, Grishin NV, Grange RW, Bassel-Duby R. Concerted regulation of myofiber-specific gene expression and muscle performance by the transcriptional repressor Sox6. Proc Natl Acad Sci U S A 2011 Jun;108(25):10196-201.
  • 56. Delahanty RJ, Beeghly-Fadiel A, Xiang YB, Long J, Cai Q, Wen W. Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol 2011 Nov;174(10):1115-26.
  • 57. Liu YZ, Pei YF, Liu JF, Yang F, Guo Y, Zhang L. Powerful bivariate genome-wide association analyses suggest the SOX6 gene influencing both obesity and osteoporosis phenotypes in males. PLoS One 2009 Aug;4(8):e6827.
  • 58. Giger JM, Haddad F, Qin AX, Baldwin KM. In vivo regulation of the beta-myosin heavy chain gene in soleus muscle of suspended and weight-bearing rats. Am J Physiol Cell Physiol 2000 Jun;278(6):C1153-61.
  • 59. Niro C, Demignon J, Vincent S, Liu Y, Giordani J, Sgarioto N. Six1 and Six4 gene expression is necessary to activate the fast-type muscle gene program in the mouse primary myotome. Dev Biol 2010 Feb;338(2):168-82.
  • 60. Tsika RW, Schramm C, Simmer G, Fitzsimons DP, Moss RL, Ji J. Overexpression of TEAD-1 in transgenic mouse striated muscles produces a slower skeletal muscle contractile phenotype. J Biol Chem 2008 Dec;283(52):36154-67.
  • 61. Richard AF, Demignon J, Sakakibara I, Pujol J, Favier M, Strochlic L. Genesis of muscle fiber-type diversity during mouse embryogenesis relies on Six1 and Six4 gene expression. Dev Biol 2011 Nov;359(2):303-20.
  • 62. Sugden MC, Zariwala MG, Holness MJ. PPARs and the orchestration of metabolic fuel selection. Pharmacol Res 2009 Sep;60(3):141-50.
  • 63. Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 2002 Apr;51(4):901-9.
  • 64. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circl Res 2003 Mar;92(5):518-24.
  • 65. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004 Oct;2(10):e294.
  • 66. Narkar VA, Fan W, Downes M, Yu RT, Jonker JW, Alaynick WA. Exercise and PGC-1α-independent synchronization of type I muscle metabolism and vasculature by ERRγ. Cell Metabol 2011 Mar 2;13(3):283-93.
  • 67. Matsakas A, Yadav V, Lorca S, Evans RM, Narkar VA. Revascularization of ischemic skeletal muscle by estrogen-related receptor-γ. Circ Res 2012 Apr;110(8):1087-96.
  • 68. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 2005 Jun;1(6):361-70.
  • 69. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002 Aug;418(6899):797-801.
  • 70. Yamamoto H, Williams EG, Mouchiroud L, Cantó C, Fan W, Downes M. NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell 2011 Nov;147(4):827-3.
  • 71. Pérez-Schindler J, Summermatter S, Salatino S, Zorzato F, Beer M, Balwierz PJ. The corepressor NCoR1 antagonizes PGC-1α and estrogen-related receptor α in the regulation of skeletal muscle function and oxidative metabolism. Mol Cell Biol 2012 Dec;32(24):4913-24.
  • 72. McCarthy JJ . The MyomiR network in skeletal muscle plasticity. Exerc Sport Sci Rev 2011 Jul;39(3):150-4.
  • 73. Williams AH, Liu N, van Rooij E, Olson EN. MicroRNA control of muscle development and disease. Curr Opin Cell Biol 2009 Jun;21(3):461-9.
  • 74. McCarthy JJ, Esser KA, Peterson CA, Dupont-Versteegden EE. Evidence of MyomiR network regulation of beta-myosin heavy chain gene expression during skeletal muscle atrophy. Physiol Genomics 2009 Nov;39(3):219-26.
  • 75. Van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009 Nov;17(5):662-73.
  • 76. Aoi W, Naito Y, Mizushima K, Takanami Y, Kawai Y, Ichikawa H. The microRNA miR-696 regulates PGC-1{alpha} in mouse skeletal muscle in response to physical activity. Am J Physiol Endocrinol Metab 2010 Apr;298(4):E799-806.
  • 77. Safdar A, Abadi A, Akhtar M, Hettinga BP, Tarnopolsky MA. miRNA in the regulation of skeletal muscle adaptation to acute endurance exercise in C57Bl/6J male mice. PLoS One 2009;4(5):e5610.
  • 78. Selsby JT, Morine KJ, Pendrak K, Barton ER, Sweeney HL. Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS One 2012;7(1):e30063.
  • 79. Von Maltzahn J, Renaud JM, Parise G, Rudnicki MA. Wnt7a treatment ameliorates muscular dystrophy. Proc Natl Acad Sci U S A 2012 Dec;109(50):20614-9.
  • 80. Stupka N, Plant DR, Schertzer JD, Emerson TM, Bassel–Duby R, Olson EN. Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice. J Physiol 2006 Sep;575(Pt 2):645-56.
  • 81. Stupka N, Schertzer JD, Bassel-Duby R, Olson EN, Lynch GS. Stimulation of calcineurin Aalpha activity attenuates muscle pathophysiology in mdx dystrophic mice. Am J Physiol Regulat Integ Comp Physiol 2008 Mar;294(3):R983-92.
  • 82. Chakkalakal JV, Harrison MA, Carbonetto S, Chin E, Michel RN, Jasmin BJ. Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Human Mol Genet 2004 Feb;13(4):379-88.
  • 83. Chakkalakal JV, Stocksley MA, Harrison MA, Angus LM, Deschenes-Furry J, St-Pierre S. Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc Natl Acad Sci USA 2003 Jun;100(13):7791-6.
  • 84. Ljubicic V, Miura P, Burt M, Boudreault L, Khogali S, Lunde JA. Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Human Mol Genet 2011 Sep;20(17):3478-93.
  • 85. Miura P, Chakkalakal JV, Boudreault L, Bélanger G, Hébert RL, Renaud JM. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Human Mol Genet 2009 Dec;18(23):4640-9.
  • 86. Gerrits MF, Ghosh S, Kavaslar N, Hill B, Tour A, Seifert EL. Distinct skeletal muscle fiber characteristics and gene expression in diet-sensitive versus diet-resistant obesity. J Lipid Res 2010 Aug;51(8):2394-404.
Licensee to OAPL (UK) 2013. Creative Commons Attribution License (CC-BY)
Keywords